https://doi.org/10.4081/monaldi.2024.2865

Evaluation of patients’ satisfaction with domiciliary biological treatment in severe asthma: a Portuguese survey

Early Access
Submitted: December 4, 2023
Accepted: March 14, 2024
Published: March 20, 2024
Severe asthma, biologics, at-home treatment
Abstract Views: 354
PDF_EARLY VIEW: 149
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Joana Lourenço
jlourenco.1717@gmail.com
https://orcid.org/0000-0002-3351-3422
Pulmonology Department, Pedro Hispano Hospital, Matosinhos Local Health Unit, Oporto, Portugal.
Ana Paula Vaz
https://orcid.org/0000-0001-9732-4754
Pulmonology Department, Pedro Hispano Hospital, Matosinhos Local Health Unit, Oporto, Portugal.
Rosa Anita Fernandes
Immuno-allergology Unit, Pedro Hispano Hospital, Matosinhos Local Health Unit, Oporto, Portugal.
Cristina Lopes
Immuno-allergology Unit, Pedro Hispano Hospital, Matosinhos Local Health Unit, Oporto, Portugal.
Ana Luísa Fernandes
Pulmonology Department, Pedro Hispano Hospital, Matosinhos Local Health Unit, Oporto, Portugal.

Dear Editor,
According to GINA, severe asthma is defined as uncontrolled asthma, despite therapy adherence with an optimized high dose of inhaled corticosteroid plus long-acting ß2-agonist coupled with management of modifiable factors/comorbidities, that worsens when this treatment is decreased. It affects a significant portion of asthmatic patients and imposes a high risk of exacerbations and mortality, which are associated with significant healthcare costs and psychosocial impact...

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
GINA. 2023 GINA report, global strategy for asthma management and prevention. 2023. Available from: https://ginasthma.org/2023-gina-main-report/.
Lombardi C, Bagnasco D, Passalacqua G. Biological agents for severe asthma: the evolution of the at-home self-injection approach. Curr Opin Allergy Clin Immunol 2020;20:421-7. DOI: https://doi.org/10.1097/ACI.0000000000000656
Sitek A, Li JT, Pongdee T. Risks and safety of biologics: a practical guide for allergists. World Allergy Organ J 2023;16:100737. DOI: https://doi.org/10.1016/j.waojou.2022.100737
Blok F, Kocks J, Wouters H, et al. Perceptions on home-administration of biologics in the context of severe asthma: an international qualitative study. J Aller Cl Imm-Pract 2022;10:2312-23.e2. DOI: https://doi.org/10.1016/j.jaip.2022.04.015

Ethics Approval

The study protocol was approved by the Ethics Committee for Health of ULS Matosinhos (institutional committee of the Pedro Hispano Hospital), document no 86/CES/JAS.

How to Cite

Lourenço, Joana, Ana Paula Vaz, Rosa Anita Fernandes, Cristina Lopes, and Ana Luísa Fernandes. 2024. “Evaluation of patients’ Satisfaction With Domiciliary Biological Treatment in Severe Asthma: A Portuguese Survey”. Monaldi Archives for Chest Disease, March. https://doi.org/10.4081/monaldi.2024.2865.
Copyright (c) 2024 The Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.